VAS
IBB icon

Valicenti Advisory Services’s iShares Biotechnology ETF IBB Stock Holding History

Valicenti Advisory Services’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Sell
13,280
-15
-0.1% -$2.58K 0.48% 50
2026
Q1 		$2.25M Sell
13,295
-225
-2% -$38.5K 0.49% 48
2025
Q4 		$2.28M Sell
13,520
-405
-3% -$65.8K 0.48% 48
2025
Q3 		$2.01M Sell
13,925
-765
-5% -$104K 0.43% 50
2025
Q2 		$1.86M Sell
14,690
-380
-3% -$46.6K 0.43% 51
2025
Q1 		$1.93M Sell
15,070
-540
-3% -$73.2K 0.5% 49
2024
Q4 		$2.06M Sell
15,610
-70
-0.4% -$9.84K 0.51% 48
2024
Q3 		$2.28M Sell
15,680
-1,165
-7% -$169K 0.59% 43
2024
Q2 		$2.31M Sell
16,845
-1,205
-7% -$161K 0.62% 39
2024
Q1 		$2.48M Sell
18,050
-1,560
-8% -$213K 0.69% 36
2023
Q4 		$2.66M Sell
19,610
-32,987
-63% -$4.02M 0.81% 34
2023
Q3 		$6.43M Sell
52,597
-5,400
-9% -$687K 2.2% 12
2023
Q2 		$7.36M Sell
57,997
-575
-1% -$74.7K 2.33% 14
2023
Q1 		$7.57M Sell
58,572
-1,004
-2% -$131K 2.52% 13
2022
Q4 		$7.82M Sell
59,576
-3,360
-5% -$434K 2.85% 10
2022
Q3 		$7.36M Sell
62,936
-1,605
-2% -$199K 2.69% 9
2022
Q2 		$7.59M Sell
64,541
-101
-0.2% -$12K 2.48% 10
2022
Q1 		$8.42M Buy
64,642
+1,335
+2% +$174K 2.21% 12
2021
Q4 		$9.66M Buy
63,307
+470
+0.7% +$72.8K 2.4% 11
2021
Q3 		$10.2M Sell
62,837
-760
-1% -$128K 2.75% 8
2021
Q2 		$10.4M Sell
63,597
-784
-1% -$121K 2.88% 7
2021
Q1 		$9.69M Sell
64,381
-499
-0.8% -$79.3K 2.87% 8
2020
Q4 		$9.83M Sell
64,880
-3,098
-5% -$443K 3.18% 7
2020
Q3 		$9.21M Sell
67,978
-730
-1% -$99K 3.43% 6
2020
Q2 		$9.39M Sell
68,708
-9,454
-12% -$1.21M 3.83% 5
2020
Q1 		$8.42M Sell
78,162
-1,275
-2% -$147K 4.21% 5
2019
Q4 		$9.57M Buy
79,437
+629
+0.8% +$70.2K 4.01% 5
2019
Q3 		$7.84M Sell
78,808
-7
-0% -$733 3.73% 5
2019
Q2 		$8.6M Sell
78,815
-799
-1% -$85K 4.19% 5
2019
Q1 		$8.9M Sell
79,614
-15,050
-16% -$1.65M 4.25% 5
2018
Q4 		$9.13M Buy
94,664
+440
+0.5% +$46.7K 4.56% 4
2018
Q3 		$11.5M Sell
94,224
-1,280
-1% -$151K 4.98% 4
2018
Q2 		$10.5M Sell
95,504
-444
-0.5% -$47.5K 4.83% 4
2018
Q1 		$10.2M Buy
95,948
+200
+0.2% +$22.2K 4.84% 4
2017
Q4 		$10.2M Sell
95,748
-258
-0.3% -$27.6K 5.08% 5
2017
Q3 		$10.7M Sell
96,006
-633
-0.7% -$67.7K 5.37% 3
2017
Q2 		$9.99M Buy
96,639
+663
+0.7% +$65.3K 5.34% 4
2017
Q1 		$9.38M Buy
95,976
+5,394
+6% +$516K 5.21% 4
2016
Q4 		$8.01M Sell
90,582
-2,469
-3% -$225K 5% 4
2016
Q3 		$8.98M Sell
93,051
-720
-0.8% -$68.5K 5.88% 3
2016
Q2 		$8.04M Buy
93,771
+4,479
+5% +$402K 5.1% 4
2016
Q1 		$7.76M Buy
89,292
+9,156
+11% +$819K 5.11% 5
2015
Q4 		$9.04M Buy
80,136
+495
+0.6% +$53.7K 6.1% 2
2015
Q3 		$8.05M Buy
79,641
+14,400
+22% +$1.73M 5.31% 2
2015
Q2 		$8.02M Sell
65,241
-1,530
-2% -$183K 5.13% 2
2015
Q1 		$7.64M Sell
66,771
-19,056
-22% -$2.1M 4.78% 2
2014
Q4 		$8.68M Sell
85,827
-3,255
-4% -$316K 5.19% 2
2014
Q3 		$8.13M Sell
89,082
-11,610
-12% -$1.02M 4.97% 2
2014
Q2 		$8.63M Buy
100,692
+7,590
+8% +$598K 5.6% 2
2014
Q1 		$7.34M Sell
93,102
-10,410
-10% -$867K 4.64% 2
2013
Q4 		$7.83M Sell
103,512
-855
-0.8% -$60.7K 4.9% 2
2013
Q3 		$7.29M Sell
104,367
-18,699
-15% -$1.23M 4.99% 2
2013
Q2 		$7.13M Buy
+123,066
New +$7.11M 5.12% 2

Other funds holding IBB

GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
FNFDCM
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SCA
Southern Capital Advisors Jackson, Tennessee $239M AUM 22.42% 1-Year Est. Return

Valicenti Advisory Services's IBB Position: Q2 2026 in Review

Valicenti Advisory Services reduced its iShares Biotechnology ETF (IBB) stake by 0.11% in Q2 2026, selling an estimated $2.58K and leaving 13,280 shares worth $2.53M. The position accounts for 0.48% of the portfolio, ranked #50.

Valicenti Advisory Services first reported a position in IBB in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.5M in Q3 2018. 158 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Valicenti Advisory Services held 13,280 shares of iShares Biotechnology ETF worth $2.53M as of Q2 2026.
  • Valicenti Advisory Services sold 15 iShares Biotechnology ETF shares in Q2 2026, an estimated $2.58K.
  • iShares Biotechnology ETF made up 0.48% of Valicenti Advisory Services's portfolio in Q2 2026, its #50 holding.
  • Valicenti Advisory Services first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 53 quarters since.
  • Valicenti Advisory Services's iShares Biotechnology ETF position peaked at $11.5M in Q3 2018.
  • 158 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Valicenti Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.